The Cancer Drugs Fund is producing dangerous, bad data: randomise everyone, everywhere!

There are recurring howls in my work. One of them is this: in general, if you don’t know which intervention works best, then you should randomise everyone, everywhere. This is for good reason: uncertainty costs lives, through sub-optimal treatment. Wherever randomised trials are the right approach, you should embed them in routine clinical care. This is an argument I’ve made, with colleagues, in […]